ArticleBlood advances2024
Defining primary refractory large B-cell lymphoma.
Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Feasibility and outcomes of decentralized point-of-care CD19 CAR T cell for relapsed large B cell lymphoma in resource-limited settings.Molecular therapy. Oncology · 2026Article
- Predicting Primary Refractory Diffuse Large B-Cell Lymphoma: A Comparison of Machine Learning Models with the IPI Score.Journal of clinical medicine · 2026Article
- Hedgehog/GLI1 regulates EMT and cancer stem cell properties via the GLI1-Bmi1 axis in diffuse large B-cell lymphoma.Scientific reports · 2026Article
- Baseline Lactate Dehydrogenase Predicts Early Treatment Failure in Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A Real-World Cohort Study.Journal of clinical medicine research · 2026Article
- Management of Primary Refractory Diffuse Large B-Cell Lymphoma in Patients Unsuitable for CAR T-Cell Therapy.European journal of haematology · 2026Review
- Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.HemaSphere · 2026Article
- Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.Blood advances · 2026Article
- Multimodal ultrasound evaluation of refractory primary thyroid lymphoma: a case report and literature review.Gland surgery · 2026Article
- Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.BMC medicine · 2026Article
- Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B-cell lymphoma patients.British journal of haematology · 2026Article
- Superiority of high-dose cytarabine-based mobilisation over cyclophosphamide or plerixafor in primary CNS lymphoma.Annals of hematology · 2026Article
- Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B-Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts.Hematological oncology · 2025Review
- Clinical outcomes of tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma: insights from a single-center study.International journal of hematology · 2025Article
- Association analysis of intratumoral metabolic heterogeneity assessed by the hottest lesion based onQuantitative imaging in medicine and surgery · 2025Article
- Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.HemaSphere · 2025Article
- Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis.Blood neoplasia · 2025Article
- Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphoma.Blood cancer journal · 2025Article
- Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies.Journal of hematology & oncology · 2025Review
- Treatment outcomes in elderly patients ≥ 65 years with Large B-Cell Lymphoma (LBCL): a real-world single center experience focusing on potential CD19-CAR-T eligibility in second line.Annals of hematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
abstractPatients with large B-cell lymphoma (LBCL) that fail to achieve a complete response (CR) or who relapse early after anthracycline-containing immunochemotherapy (IC) have a poor prognosis and are commonly considered to have "primary refractory disease." However, different definitions of primary refractory disease are used in the literature and clinical practice. In this study, we examined variation in the time to relapse used to define refractory status and association with survival outcomes in patients with primary refractory LBCL in a single-center prospective cohort with validation in an independent multicenter cohort. Patients with newly diagnosed LBCL were enrolled in the Molecular Epidemiological Resource cohort (MER; N = 949) or the Lymphoma Epidemiology of Outcomes cohort (LEO; N = 2755) from September 2002 to May 2021. Primary refractory LBCL was defined as no response (stable disease [SD]) or progressive disease (PD) during, or by the end of, frontline (1L) IC (primary PD; PPD); partial response at end of treatment (EOT PR); or relapse within 3 to 12 months after achieving CR at EOT to 1L IC (early relapse). In the MER cohort, patients with PPD had inferior overall survival (OS; 2-year OS rate: 15% MER, 31% LEO) when compared with other subgroups considered in defining primary refractory disease, EOT PR (2-year OS rate: 38% MER, 50% LEO) and early relapse (2-year OS rate: 44% MER, 58% LEO). Among patients receiving 1L IC with curative intent, we identified that patients with PPD are the key subgroup with poor outcomes. We propose a definition of primary refractory LBCL as SD or PD during, or by the end of, 1L treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.